It should be noted that these GRPR-agonist-based radiopeptides typically display high internalization rates in cancer cell lines, such as in human androgen-independent prostate adenocarcinoma PC-3 cells or human breast T-47D cells broadly used as GRPR-positive cell models. This evidence concerns the gene GRPR and cancer.